Eli Lilly’s obesity drug Zepbound shows benefits in heart failure patients

Taking stock of the drug industry, from the lab to the medicine chest

August 1, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Illustration: STAT; Source: Eli Lilly/AP STAT+ | Eli Lilly's obesity drug Zepbound shows benefits in heart failure patients It's the second GLP-1 drug to show positive results in the disease area after Novo Nordisk's Wegovy, but different trial designs make comparisons difficult. By Elaine Chen Opinion: PBMs aren't opening access to lower-cost biosimilars. Reform is needed now First Opinion: PBMs actively deny patients access to low-cost, safe, and effective drugs, including biosimilars for drugs like Humira, to protect profits. By Juliana M. Reed STAT+ | With new data, Regenxbio advances plan for Duchenne gene therapy The therapy was administered to two more boys and produced high levels of a miniaturized version of the protein needed for muscles to function properly. By Adam Feuerstein Illustration: Christine Kao/STAT; Photos: Getty Images, AP, GSK, CDC, NIAID Behind the malaria vaccines: A 40-year quest against one of humanity's biggest killers Hundreds of thousands die from malaria yearly. Two vaccines now deployed in Africa represent a new chapter in efforts to vanquish killer disease. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser